Lanean...
Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure
AIM: First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0.05 μM [T(c >0.05)]). Second, screen additional pharmacogenes for associations with T(c >0.05). METHODS: Pharmacogene panel gen...
Gorde:
| Argitaratua izan da: | Pharmacogenomics |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Future Medicine Ltd
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6562943/ https://ncbi.nlm.nih.gov/pubmed/30520341 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pgs-2018-0162 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|